STING-targeted PET tracer for early assessment of tumor immunogenicity in colorectal cancer after chemotherapy.
Purpose: To optimize chemotherapy regimens and improve the effectiveness of chemotherapy combined with immunotherapy, a PET tracer specifically targeting the stimulator of interferon genes (STING), denoted as [18F]FBTA was used to monitor the early changes in tumor immunogenicity after chemotherapy...
| Published in: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 51; no. 3; pp. 641 - 656 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Published: |
Springer Nature
Feb2024
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=174879054&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 174879054 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 16197070 NPC jtl: European Journal of Nuclear Medicine & Molecular Imaging issn: 16197070 maglogo: N pubinfo: dt: Feb2024 vid: 51 iid: 3 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 174879054 173394471 10.1007/s00259-023-06485-w 174879054 ppf: 641 ppct: 15 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: STING-targeted PET tracer for early assessment of tumor immunogenicity in colorectal cancer after chemotherapy. aug: au: Xu, Duo Lu, Xin Yang, Fan Jiang, Zebo Yang, Shirui Bi, Lei Liu, Jiani Shan, Hong Li, Dan affil: https://ror.org/0064kty71 Department of Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-Sen University, 519000, Zhuhai, China sug: ab: Purpose: To optimize chemotherapy regimens and improve the effectiveness of chemotherapy combined with immunotherapy, a PET tracer specifically targeting the stimulator of interferon genes (STING), denoted as [18F]FBTA was used to monitor the early changes in tumor immunogenicity after chemotherapy in colorectal cancer (CRC) mice. Methods: The toluene sulfonate precursor was labeled with 18F to produce the STING targeted probe—[18F]FBTA. [18F]FBTA-PET imaging and biodistribution were performed using CRC mice treated with oxaliplatin (OXA) or cisplatin (CDDP). CRC mice were also treated with low (CDDP-LD: 1 mg/kg) or medium (CDDP-MD: 2.5 mg/kg) doses of CDDP, and subjected to PET imaging and biodistribution. The effects of different chemotherapeutic agents and different doses of CDDP on tumor innate immunity were verified by flow cytometry and immunohistochemistry. Results: PET imaging of CRC mice exhibited notably enhanced tumor uptake in the early phase of chemotherapy with treatment with OXA (3.09 ± 0.25%ID/g) and CDDP (4.01 ± 0.18%ID/g), especially in the CDDP group. The PET-derived tumor uptake values have strong correlations with STING immunohistochemical score. Flow cytometry showed both agents led to DCs and macrophages infiltration in tumors. Compared with OXA, CDDP treatment recruits more DCs and macrophages in CRC tumors. Both CDDP-LD and CDDP-MD treatment elevated uptake in CRC tumors, especially in CDDP-MD group. Immunohistochemistry and flow cytometry confirmed CDDP-MD treatment recruits more DCs and macrophages than CDDP-LD treatment. Conclusion: Overall, the STING-targeted tracer—[18F]FBTA was demonstrated to monitor early changes in tumor immunogenicity in CRC mice after chemotherapy. Besides, the STING-targeted strategy may help to select the appropriate chemotherapy regimen, including chemotherapeutic agents and doses, which further improve clinical decision making for combination immunotherapy after chemotherapy for CRC. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|